Bleeding in patients with hemato-oncological disease in relation to platelet function (BOP study)

Bleeding in patients with hemato-oncological disease in relation to platelet function (BOP study) - BOP study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47418

Enrollment

160

Registered

2016-04-07

Start date

2016-06-06

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with hemato-oncological disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age * 18 years. Expected platelet transfusion support (platelet count

Exclusion criteria

Exclusion criteria: Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP The use of anti-coagulant drugs or drugs affecting platelet function

Design outcomes

Primary

Measure	Time frame
Primary Objective: To assess the relation between bleeding tendency (patients with WHO grade II or more) and platelet function and platelet /count.	—

Secondary

Measure	Time frame
1. To assess the relation between bleeding tendency (all grades) and platelet function and platelet count. 2. To assess the percentage of days with WHO grade II or more bleeding and platelet function. 3. To assess the relation between vascular damage (endothelial cell markers in plasma) and bleeding tendency (all grades). 4. To assess the bleeding observation score, vascular damage and platelet function in patients upon remission-induction chemotherapy for acute leukemia/ myelodysplastic syndrome and other diseases. 5. To assess the influence of infection (SIRS criteria) on the bleeding observation score, vascular damage and platelet function. 6. To assess the influence of platelet transfusions on the health related quality of life in thrombocytopenic hemato-oncological patients.	—

Measure

Time frame

1. To assess the relation between bleeding tendency (all grades) and platelet function and platelet count. 2. To assess the percentage of days with WHO grade II or more bleeding and platelet function. 3. To assess the relation between vascular damage (endothelial cell markers in plasma) and bleeding tendency (all grades). 4. To assess the bleeding observation score, vascular damage and platelet function in patients upon remission-induction chemotherapy for acute leukemia/ myelodysplastic syndrome and other diseases. 5. To assess the influence of infection (SIRS criteria) on the bleeding observation score, vascular damage and platelet function. 6. To assess the influence of platelet transfusions on the health related quality of life in thrombocytopenic hemato-oncological patients.

—

Countries

Netherlands

Outcome results